Exelixis, Inc. (EXEL)
54.64
+0.19
(+0.35%)
USD |
NASDAQ |
Aug 31, 16:00
54.70
+0.06
(+0.11%)
After-Hours: 20:00
Exelixis Total Long Term Debt (Quarterly) : 165.93M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 165.93M |
| March 31, 2026 | 169.54M |
| December 31, 2025 | 173.04M |
| September 30, 2025 | 176.46M |
| June 30, 2025 | 179.84M |
| March 31, 2025 | 187.12M |
| December 31, 2024 | 190.82M |
| September 30, 2024 | 194.44M |
| June 30, 2024 | 198.02M |
| March 31, 2024 | 201.47M |
| December 31, 2023 | 189.94M |
| September 30, 2023 | 190.86M |
| June 30, 2023 | 194.69M |
| March 31, 2023 | 186.95M |
| December 31, 2022 | 190.17M |
| September 30, 2022 | 159.84M |
| June 30, 2022 | 161.02M |
| March 31, 2022 | 50.64M |
| December 31, 2021 | 51.27M |
| September 30, 2021 | 52.25M |
| June 30, 2021 | 53.22M |
| March 31, 2021 | 52.84M |
| December 31, 2020 | 49.09M |
| September 30, 2020 | 47.63M |
| June 30, 2020 | 48.33M |
| Date | Value |
|---|---|
| March 31, 2020 | 47.88M |
| December 31, 2019 | 48.01M |
| September 30, 2019 | 23.76M |
| June 30, 2019 | 22.59M |
| March 31, 2019 | 19.96M |
| December 31, 2018 | 12.31M |
| September 30, 2018 | 0.139M |
| June 30, 2018 | 20.65M |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 113.35M |
| December 31, 2016 | 189.12M |
| September 30, 2016 | 190.86M |
| June 30, 2016 | 396.06M |
| March 31, 2016 | 388.66M |
| December 31, 2015 | 417.94M |
| September 30, 2015 | 377.89M |
| June 30, 2015 | 371.22M |
| March 31, 2015 | 368.43M |
| December 31, 2014 | 361.66M |
| September 30, 2014 | 355.22M |
| June 30, 2014 | 348.97M |
| March 31, 2014 | 343.02M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 2.942B |
| BioMarin Pharmaceutical, Inc. | 4.186B |
| Cytokinetics, Inc. | 1.250B |
| Emergent BioSolutions, Inc. | 586.70M |
| Gilead Sciences, Inc. | 26.25B |